CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Key Points Response to the CD38-targeting antibody daratumumab is significantly associated with CD38 expression levels on the tumor cells. Resistance to daratumumab is accompanied by increased expression of complement-inhibitory...